GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » Short-Term Capital Lease Obligation

LIPO (Lipella Pharmaceuticals) Short-Term Capital Lease Obligation : $0.09 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals Short-Term Capital Lease Obligation?

Lipella Pharmaceuticals's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.09 Mil.

Lipella Pharmaceuticals's quarterly Short-Term Capital Lease Obligation increased from Dec. 2023 ($0.09 Mil) to Mar. 2024 ($0.09 Mil) and increased from Mar. 2024 ($0.09 Mil) to Jun. 2024 ($0.09 Mil).

Lipella Pharmaceuticals's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.04 Mil) to Dec. 2022 ($0.06 Mil) and increased from Dec. 2022 ($0.06 Mil) to Dec. 2023 ($0.09 Mil).


Lipella Pharmaceuticals Short-Term Capital Lease Obligation Historical Data

The historical data trend for Lipella Pharmaceuticals's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals Short-Term Capital Lease Obligation Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Short-Term Capital Lease Obligation
0.05 0.04 0.06 0.09

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Short-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.09 0.09 0.09 0.09

Lipella Pharmaceuticals Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.


Lipella Pharmaceuticals Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipella Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
N/A
Address
7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.
Executives
Lori Birder director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman director, 10 percent owner, officer: See Remarks C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston officer: Chief Financial Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor director, 10 percent owner, officer: Chief Medical Officer C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura director C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208